Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on March 16, 2011, reporting events occurring on March 15, 2011. The filing addresses a determination by the Audit Committee that previously issued financial statements for the fiscal year ended December 31, 2009, and the quarters ended March 31, June 30, and September 30, 2010, can no longer be relied upon due to accounting errors regarding warrant and anti-dilution provision classifications.
Key Financial Metrics and Adjustments
The filing details specific retroactive accounting adjustments required by ASC 480 and ASC 815. The filing text does not provide current revenue, profit, cash flow, or liquidity figures for the reporting period, as the focus is on restating prior periods. The quantified impacts for the year ended December 31, 2009, are as follows:
- Net Loss: Decreased by $3,484,330.
- Accumulated Deficit: Decreased by $1,092,021 at the start of the year.
- Liabilities: Increased by $3,197,189.
- Additional Paid-in Capital: Decreased by $7,773,540.
Material Changes Versus Prior Period
The material change involves the reclassification of financial instruments previously treated as equity. Management determined that warrants containing net cash settlement provisions in fundamental transactions and full ratchet anti-dilution protections from 2007 and 2008 financings must be classified as liabilities measured at fair value. Consequently, changes in fair value are recognized in earnings rather than equity. This represents a significant shift from the original reporting where these items were likely classified differently.
Guidance, Outlook, and Risks
Management Commentary: Management stated the adjustments were inadvertent and based on the best judgment at the time. The company intends to file its corrected Form 10-K for the fiscal year ended December 31, 2010, on March 16, 2011, incorporating these adjustments.
Internal Controls: Management concluded that previous conclusions regarding the effectiveness of internal controls over financial reporting were inadequate. Remediation steps were implemented in the fourth quarter of 2010.
Risks: The filing includes standard forward-looking statement disclaimers regarding pharmaceutical development difficulties, regulatory approvals, clinical testing success, and the need for additional financing.
Investor Verification Checklist
- Verify the corrected financial statements in the upcoming Form 10-K for the fiscal year ended December 31, 2010.
- Confirm the current fair value of the reclassified warrant and anti-dilution liabilities.
- Review the updated assessment of internal controls over financial reporting in the 10-K.
- Monitor the company's liquidity position given the increase in reported liabilities.
- Clarify the discrepancy between the request metadata (Opus Genetics) and the filing issuer (Rexahn Pharmaceuticals).